MetaCap

Satellos Bioscience (MSLE) vs Sionna Therapeutics (SION)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Satellos Bioscience (MSLE) has outperformed Sionna Therapeutics (SION) over the past year, losing 5.3% versus a loss of 93.5%. Sionna Therapeutics is the larger company by market cap ($127.8 million vs $120.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MSLE-5.33%SION-93.53%
+127%+12%-104%
Nov 21, 20251 yearNov 20, 2026
MSLE-12.51%SION-88.70%
+114%+8%-98%
Feb 3, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MSLE versus SION key metrics
MetricMSLESION
Share price$5.68$2.83
Market cap$120.51M$127.79M
1-day change-2.07%-4.88%
YTD return-3.40%-93.13%
1-year return-5.33%-93.53%
5-year return-58.48%—
EPS (TTM)$-2.12$-2.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-24.87M$-75.27M
52-week high$13.40$54.97
52-week low$5.44$2.75
Distance from 52-week high-57.60%-94.86%
Analyst consensusstrong_buyhold
Avg. price target upside+325.53%+643.36%
Average volume51.19K1.12M
Shares outstanding21.22M45.24M
Employees1859
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MSLE has outperformed SION by 88.2 percentage points over the past year.

About Satellos Bioscience

MSLE stock →

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.

Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees

About Sionna Therapeutics

SION stock →

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees

MSLE vs SION FAQ

Which is bigger, Satellos Bioscience or Sionna Therapeutics?

Sionna Therapeutics (SION) is larger, with a market capitalization of $127.79M compared with $120.51M for Satellos Bioscience (MSLE).

Which stock has performed better over the past year, MSLE or SION?

MSLE returned -5.33% over the past 12 months, compared with -93.53% for SION (price return, excluding dividends). Past performance does not predict future results.

Are Satellos Bioscience and Sionna Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons